glp 1 drugs and crohn's disease Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, therapeutic potential GLP-1 Medications: Reimagining the Treatment

Tirzepatide: first Approval

Sampedros team ( 4.4 Long-term safety and off-target effects Emerging reports link GLP-1RAs to rare ocular adverse events, including NAION ( 5 Conclusion In conclusion, the expanding body of evidence supports that GLP-1RAs offer a multifaceted approach to ocular therapeutics by targeting key molecular pathways involved in retinal neuroprotection, mitochondrial regulation, inflammation, vascular remodeling, and angiogenesis

Structural Basis for GLP-1 Receptor Activation by LY3502970, an Orally Active Nonpeptide Agonist

GLP-1 receptor activation appears to release the accelerator (reducing inflammatory effector cells) while strengthening the brake (enhancing regulatory cells)

The hunger pangs you get with fasting subside and your body acclimates to burning fat as an energy source